Head-to-head · free

10x Genomics, Inc. vs Viking Therapeutics

TXG vs VKTX — return on capital, cash generation, margins and balance sheet side by side.

TXG

3 / 4

measures where TXG leads

VKTX

1 / 4

measures where VKTX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureTXG · FY2025VKTX · FY2025
Revenue$642.8M$0
Net income(43.5M)(359.6M)
Revenue growth (yearly, multi-year)7.0%—
Free cash flow$130.1M—
Free cash flow margin20.2%—
Net cash / (debt)——
ROIC——
Return on equity-5.8%-47.3%
Gross margin69.1%—
Operating margin-17.2%—
Net debt / EBITDA27.61x0.42x

Figures are as reported by each company; latest fiscal year shown.

Where 10x Genomics, Inc.'s cash went (FY2025)

Capital spending
$5.9M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TXG profile →

Where Viking Therapeutics's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full VKTX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons